Patents by Inventor Cheuk-Yui Leung
Cheuk-Yui Leung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230338283Abstract: Disclosed is a pharmaceutical mini-tablet comprising mitapivat or a pharmaceutically acceptable salt thereof, and in a particular embodiment comprising a mitapivat sulfate salt, and one or more inactive ingredients selected from a filler, disintegrant, lubricant, binder, and diluent.Type: ApplicationFiled: September 24, 2021Publication date: October 26, 2023Inventors: Cheuk-Yui Leung, Eric Simone, Ophelia Qiping Yin
-
Publication number: 20220362195Abstract: The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides various dosage forms and methods of treating a disease or disorder (e.g., multiple sclerosis).Type: ApplicationFiled: February 22, 2022Publication date: November 17, 2022Inventors: Pierre Boulas, Erwin Irdam, Shyam B. Karki, William F. Kiesman, Cheuk-Yui Leung, Yiqing Lin, Andrea Trementozzi, Peter Zawaneh
-
Patent number: 11291642Abstract: The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides various dosage forms and methods of treating a disease or disorder (e.g., multiple sclerosis).Type: GrantFiled: June 15, 2016Date of Patent: April 5, 2022Assignee: BIOGEN MA INC.Inventors: Pierre Boulas, Erwin Irdam, Shyam B. Karki, William F. Kiesman, Cheuk-Yui Leung, Yiqing Lin, Andrea Trementozzi, Peter Zawaneh
-
Patent number: 11197842Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: GrantFiled: November 19, 2015Date of Patent: December 14, 2021Assignee: BIOGEN MA INC.Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi
-
Publication number: 20210369629Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: ApplicationFiled: May 13, 2021Publication date: December 2, 2021Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov
-
Patent number: 11033509Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: GrantFiled: February 8, 2017Date of Patent: June 15, 2021Assignee: BIOGEN MA INC.Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov
-
Publication number: 20190175510Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a tablet and comprise one or more extended release polymer matrix. Also provided are pharmaceutical compositions in the form of a capsule comprising one or more tablets of the present invention. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: ApplicationFiled: February 14, 2019Publication date: June 13, 2019Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Yiqing Lin
-
Publication number: 20190091146Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.Type: ApplicationFiled: November 26, 2018Publication date: March 28, 2019Applicant: Biogen MA Inc.Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan
-
Publication number: 20190083404Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a tablet and comprise one or more extended release polymer matrix. Also provided are pharmaceutical compositions in the form of a capsule comprising one or more tablets of the present invention. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: ApplicationFiled: November 19, 2015Publication date: March 21, 2019Applicants: BIOGEN MA INC., BIOGEN MA INC.Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Yiqing Lin
-
Publication number: 20190070143Abstract: The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides various dosage forms and methods of treating a disease or disorder (e.g., multiple sclerosis).Type: ApplicationFiled: June 15, 2016Publication date: March 7, 2019Inventors: Pierre Boulas, Erwin Irdam, Shyam B. Karki, William F. Kiesman, Cheuk-Yui Leung, Yiqing Lin, Andrea Trementozzi, Peter Zawaneh
-
Publication number: 20190046456Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: ApplicationFiled: February 8, 2017Publication date: February 14, 2019Applicant: BIOGEN MA INC.Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov
-
Publication number: 20190008768Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.Type: ApplicationFiled: September 14, 2018Publication date: January 10, 2019Applicant: Biogen MA Inc.Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan
-
Patent number: 10172794Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.Type: GrantFiled: December 12, 2014Date of Patent: January 8, 2019Assignee: Biogen MA Inc.Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan
-
Publication number: 20180153845Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.Type: ApplicationFiled: November 19, 2015Publication date: June 7, 2018Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi
-
Publication number: 20160310419Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.Type: ApplicationFiled: December 12, 2014Publication date: October 27, 2016Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan